• Our Team
  • Mucosal Vaccines
  • Showcase
  • News
    • Investors
    • Aptimmune Biologics Adds CEO and Technical Consultant to Management Team
    • Aptimmune Biologics and Kemin Industries Announce Partnership
    • Aptimmune Completes Series B Funding, Moves to St. Louis
    • Aptimmune Receives Iowa Biotech’s Top Company Award
    • ISU and Aptimmune Improve PRRSV Isolation
    • Aptimmune Selected by Yield Lab for Ag Tech Accelerator Program
    • Aptimmune Biologics Raises $2.75 Million
    • Novel Technology to Fight Swine Pathogens
    • Aptimmune Offering New Vaccination Technology
    • Swine Vaccine Maker at Ag Innovations Showcase
  • Join Our Team
  • Contact
  • Our Team
  • Mucosal Vaccines
  • Showcase
  • News
    • Investors
    • Aptimmune Biologics Adds CEO and Technical Consultant to Management Team
    • Aptimmune Biologics and Kemin Industries Announce Partnership
    • Aptimmune Completes Series B Funding, Moves to St. Louis
    • Aptimmune Receives Iowa Biotech’s Top Company Award
    • ISU and Aptimmune Improve PRRSV Isolation
    • Aptimmune Selected by Yield Lab for Ag Tech Accelerator Program
    • Aptimmune Biologics Raises $2.75 Million
    • Novel Technology to Fight Swine Pathogens
    • Aptimmune Offering New Vaccination Technology
    • Swine Vaccine Maker at Ag Innovations Showcase
  • Join Our Team
  • Contact

The Future of Disease Protection is Now

Aptimmune Biologics creates valuable, safe, and effective vaccines to combat economically challenging swine diseases using our proprietary Barricade platform technology. We currently focus on African Swine Fever virus (ASF) and autogenous mucosal vaccines for Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and Influenza A virus in swine (IAV-S).

Aptimmune's Technology

Our Team

Investment Opportunities

Want to know more?

Contact us.

© 2023 Aptimmune